$9.340
-0.138 (-1.48%)Zum Schluss
ADMA-News
ADMA-Events
ADMA Projects FY26 Adjusted EBITDA of $265M-$300M
Backs FY26 adjusted EBITDA view $265M-$300M. The company said, "The FY2026 outlook continues to reflect sustained competitive dynamics and pricing pressure within the U.S. immune globulin market through the balance of the year. ASCENIV is expected to remain ADMA's principal growth driver, supported by accelerating demand, expanding physician adoption and an increasing body of differentiated clinical and real-world evidence."
ADMA Q2 Revenue $124.4M, Below Consensus
Reports Q2 revenue $124.4M, consensus $125.36M. "Our second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV's growth trajectory," said Adam Grossman, President and Chief Executive Officer of ADMA. "ASCENIV continued to outperform, supported by increasing physician adoption, broader prescriber engagement, new patient starts and higher patient utilization. Growth in ASCENIV utilization accelerated in the quarter, with June delivering the strongest sequential month-over-month utilization growth since the first half of 2024. BIVIGAM demand continued to stabilize during the quarter, resulting in sequential improvement in utilization and revenue. Together, these trends reinforce our confidence in sustained growth throughout the balance of 2026."
ADMA Reports Q1 Revenue of $114.49M, Below Consensus
Reports Q1 revenue $114.49M, consensus $139.97M. "During the first quarter, the market for U.S. plasma derived therapies and immunoglobulin experienced increased competitive dynamics which, along with variability in distributor ordering patterns, created near-term topline pressures, particularly impacting BIVIGAM," said Adam Grossman, President and Chief Executive Officer of ADMA. "Importantly, these dynamics were limited to distribution and inventory behavior and we believe do not reflect any deterioration in underlying ASCENIV demand, where fundamentals remained strong and continue to improve - with record utilization growth throughout the quarter, as illustrated by ASCENIV's 28% year-over-year revenue growth. We continue to see strength across key ASCENIV demand metrics, including record new patient starts, growing prescriber breadth, product pull-through and patient adherence, and we are encouraged that the second quarter run rate based on April demand is in-line with the level of first quarter direct sales."
ADMA Sees FY26 Adjusted EBITDA of $265M to $300M
Sees FY26 adjusted EBITDA $265M-$300M. Grossman continued, "We believe the first quarter results likely represent a trough revenue baseline driven by what we anticipate is a temporary market dislocation, and we expect to drive growth over the coming quarters. Despite this backdrop, in the quarter ADMA delivered 22% year-over-year Adjusted Net Income growth, 24% Adjusted EBITDA growth, expanded gross margins to 71% and generated $58 million of operating cash flow on revenue that was essentially flat - underscoring the resilience of our business model in a challenging PDT and IG landscape. We believe the current pricing environment and inventory dislocation in the U.S. IG and PDT market will prove temporary, and ADMA has remained disciplined in its pricing strategy. With ASCENIV demand at record levels, supported by durable and enduring fundamentals, and still forecasted to be early in its penetration curve, we remain confident in our ability to drive growth from this baseline through expanding margins and increasing cash generation. We also see meaningful long-term opportunity in SG-001, where our capital-efficient development approach and existing platform position us to leverage our commercial infrastructure, if approved, for a potentially rapid commercial ramp toward what we believe is a $300 to $500 million annual market opportunity."
Adma Biologics Asceniv Approved by FDA for Children Aged 2 and Older
Adma Biologics announced the FDA has approved the company's supplemental biologics license application submitted under section 351 of the Public Health Service Act for Asceniv. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment. Additionally, the approval provides for a revision of Asceniv's prescribing information to expand the primary humoral immunodeficiency indication to pediatric patients two years of age and older. Previously, the indication for Asceniv was restricted to PI patients aged 12 years and older.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.